242 related articles for article (PubMed ID: 4637029)
1. Estrogenic activity in women receiving an injectable progestogen for contraception.
Mishell DR; Kharma KM; Thorneycroft IH; Nakamura RM
Am J Obstet Gynecol; 1972 Jun; 113(3):372-6. PubMed ID: 4637029
[TBL] [Abstract][Full Text] [Related]
2. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
6. Control of fertility with oral medication.
Diddle AW; Watts GF; Gardner WH; Williamson PJ
West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
[TBL] [Abstract][Full Text] [Related]
7. The effect of contraceptive steroids on hypothalamic-pituitary function.
Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
[TBL] [Abstract][Full Text] [Related]
8. Sustained effects on synthetic ovarian steroids of rat myometrial contractility.
Parkington HC; Lipton A
J Endocrinol; 1976 Aug; 70(2):223-7. PubMed ID: 965882
[TBL] [Abstract][Full Text] [Related]
9. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
[TBL] [Abstract][Full Text] [Related]
11. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
Lan PT; Aedo AR; Landgren BM; Johannisson E; Diczfalusy E
Contraception; 1984 Jan; 29(1):1-18. PubMed ID: 6234145
[TBL] [Abstract][Full Text] [Related]
12. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
[TBL] [Abstract][Full Text] [Related]
13. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
14. Studies on ovarian and adrenal steroids at different phases of the menstrual cycle. III. Steroid and lutropin levels before and after the administration of a single contraceptive dose of depot-medroxyprogesterone acetate (DMPA).
Aedo AR; Landgren BM; Diczfalusy E
Contraception; 1981 Aug; 24(2):117-35. PubMed ID: 6457729
[TBL] [Abstract][Full Text] [Related]
15. Mammary tumors and serum hormones in the bitch treated with medroxyprogesterone acetate or progesterone for four years.
Frank DW; Kirton KT; Murchison TE; Quinlan WJ; Coleman ME; Gilbertson TJ; Feenstra ES; Kimball FA
Fertil Steril; 1979 Mar; 31(3):340-6. PubMed ID: 437169
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of estrogens during long-term treatment with depo-medroxyprogesterone acetate as a contraceptive agent.
Jeppsson S; Johansson ED; Sjörberg NO
Contraception; 1973 Aug; 8(2):165-70. PubMed ID: 4768085
[TBL] [Abstract][Full Text] [Related]
17. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
Furuhjelm M; Carlström K
Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
[TBL] [Abstract][Full Text] [Related]
18. Acceptability of injectable contraceptives in Assiut, Egypt.
Salem HT; Salah M; Aly MY; Thabet AI; Shaaban MM; Fathalla MF
Contraception; 1988 Dec; 38(6):697-710. PubMed ID: 2975583
[TBL] [Abstract][Full Text] [Related]
19. A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera.
Fotherby K; Benagiano G; Toppozada HK; Abdel-Rahman A; Navaroli F; Arce B; Ramos-Cordero R; Gual C; Landgren BM; Johannisson E
Contraception; 1982 Mar; 25(3):261-72. PubMed ID: 6210485
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic study of different doses of Depo Provera.
Fotherby K; Koetsawang S; Mathrubutham M
Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
